Delivery Order SPE2DB24D2106-SPE2DB24FAUYE

Award Date 9/16/24
Potential Completion Date 9/17/24
Potential Value $9.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,587.62 contract is for the delivery of Ondansetron ODT 8 mg tablets. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a wide range of pharmaceutical products to support the medical supply...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,736.55, is for the delivery of Ondansetron ODT 4 mg tablets in 30-count packages. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. The IDC enables the DLA to issue firm fixed-price...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,083.86 firm fixed-price contract is for the delivery of 4565006417 Ondansetron ODT 4 mg tablets. The contract has an ultimate completion date of June 27, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the issuance of...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain program to DMS Pharmaceutical Group Inc., a woman-owned small business. The $2,003.65 contract is for the delivery of 4,564,668,857 units of ondansetron HCL 4 mg tablets. The contract has an ultimate completion date of May 21, 2024 and was awarded on May 20, 2024. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $1,968.95 and a period of performance through June 11, 2024. The contract is for the delivery of Ondansetron ODT 8 mg tablets to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group has a significant...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $9,148.15 contract is for the delivery of Ondansetron ODT 4 mg tablets over a period ending on July 18, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract, valued at $1,104.48, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. This order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued at up to $499,999,999, that runs through December 31, 2025. The IDC allows DLA to issue delivery orders for a comprehensive range of pharmaceutical items, including both common and...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,542.80 contract is for the delivery of 4,565,862,751 units of the prescription medication ondansetron ODT 8 mg tablets. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA to provide a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Ondansetron ODT 4 mg tablets and has a firm fixed price of $2,778.48 with a completion date of July 9, 2024. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $5,280.16 firm fixed-price contract is for the supply of Ondansetron ODT 4 mg tablets, a medication used to prevent nausea and vomiting. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a wide range of...
  • SPE2DB24D2106
    Indefinite Delivery Contract
  • SPE2DB24D2106-SPE2DB24FAUYE
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of ondansetron ODT 4 mg tablets. The contract has a ceiling value of $9,134.31 and an ultimate completion date of September 17, 2024. This order is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which provides a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. The contract has no set-aside designation.

Generated 12/16/24, 2:13 PM